Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.

被引：0
|
作者：
Goujon, Morgan [1 ]
Anota, Amelie [2 ,3 ]
Charton, Frontczak Alexandre [4 ]
Charton, Emilie [5 ,6 ]
Maurina, Tristan [1 ]
Almotlak, Hamadi [1 ]
Nguyen, Thierry [1 ]
Fabien, Calcagno [1 ]
Stein, Ulrich [1 ]
Mouillet, Guillaume [7 ]
Thiery-Vuillemin, Antoine [8 ]
机构：
[1] Univ Hosp, Dept Med Oncol, Besancon, France
[2] Univ Hosp Besancon, Qual Life Oncol Clin Res Platform, Besancon, France
[3] Univ Hosp Besancon, Methodol & Qual Life Oncol, INSERM UMR 1098, Besancon, France
[4] Univ Hosp, Dept Urol, Besancon, France
[5] Univ Hosp Besancon, Methodol & Qual Life Unit, Dept Oncol, INSERM UMR 1098, Besancon, France
[6] French Natl Platform Qual Life & Canc, Besancon, France
[7] Univ Hosp, Dept Med Oncol, Methodol & Qual Life Unit Oncol, INSERM UMR 1098, Besancon, France
[8] Univ Hosp, Dept Med Oncol, INSERM UMR 1098, Besancon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.54
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
54
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.
    Clarke, Noel W.
    Thiery-Vuillemin, Antoine
    Wiechno, Pawel J.
    Alekseev, Boris
    Sala, Nuria
    Jones, Robert
    Kocak, Ivo
    Chiuri, Vincenzo Emanuele
    Jassem, Jacek
    Flechon, Aude
    Redfern, Charles
    Goessl, Carsten Dietrich
    Burgents, Joseph
    Gresty, Christopher
    Degboe, Arnold
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Association between nutritional status (NS) and health-related quality of life (HRQoL) in men with early metastatic castrate-resistant prostate cancer (mCRPC).
    Cavka, Luka
    Perme, Maja Pohar
    Kozjek, Nada Rotovnik
    Seruga, Bostjan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Groshen, Susan G.
    Quinn, David I.
    Goldkorn, Amir
    Martel, Cynthia L.
    Pinski, Jacek K.
    Kuhn, Pater
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [5] Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone
    Osoba, D
    Tannock, IF
    Ernst, DS
    Neville, AJ
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1654 - 1663
  • [6] A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Zurita, A.
    Shore, N. D.
    Kozloff, M. F.
    Ryan, C. W.
    Beer, T. M.
    Maneval, E. Chow
    Chen, I.
    Logothetis, C. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 287 - 287
  • [7] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] Phase I Trial of the Combination of Docetaxel Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer
    Thakur, Manish K.
    Heilbrun, Lance
    Dobson, Kimberlee
    Boerner, Julie
    Stark, Karri
    Li, Jing
    Smith, Daryn
    Heath, Elisabeth
    Fontana, Joseph
    Vaishampayan, Ulka
    CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : E695 - E703
  • [9] Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA plus P).
    Gotto, Geoffrey
    Fradet, Vincent
    Drachenberg, Darrel
    Sabbagh, Robert
    Rendon, Ricardo A.
    Shayegan, Bobby
    Danielson, Brita Lavender
    Casey, Richard
    Chan, Katherine
    Camacho, Fernando
    Zardan, Anousheh
    Hew, Huong
    Feifer, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA plus AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
    Oudard, S. M.
    Bevans, K. B.
    Attard, G.
    Efstathiou, E.
    Flaig, T. W.
    Franke, F. A.
    Goodman, O. B., Jr.
    De Giorgi, U.
    Pieczonka, C. M.
    Yeruva, K.
    De Porre, P.
    Brookman-May, S. D.
    Dibaj, S.
    Wu, D.
    Mundle, S. D.
    McCarthy, S.
    Steuber, T.
    Suzuki, H.
    Rathkopf, D. E.
    Saad, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S634 - S634
12345